Patents by Inventor Philippe Walker

Philippe Walker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated human and rat GAL-R2 galanin receptors
    Patent number: 7528229
    Abstract: The present invention is directed to a novel receptor for galanin which has been designated as galanin receptor 2. The invention encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to methods and compositions which rely upon either GAL-R2 proteins or nucleic acids.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: May 5, 2009
    Assignee: National Research Council of Canada
    Inventors: Shen Shi-Hsiang, Ahmad Sultan, Claes Wahlestedt, Philippe Walker
  • Assay employing human or rat GAL-R2 galanin receptor
    Patent number: 7510846
    Abstract: The present invention is directed to a novel receptor for galanin which has been designated as galanin receptor 2. The invention encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to methods and compositions which rely upon either GAL-R2 proteins or nucleic acids.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: March 31, 2009
    Assignee: National Research Council of Canada
    Inventors: Shi-Hsiang Shen, Sultan Ahmad, Claes Wahlestedt, Philippe Walker
  • Methods for assaying expression of novel galanin receptors
    Patent number: 7407761
    Abstract: The present invention is directed to methods for assaying a test compound's ability to alter the expression of novel receptor for galanin which has been designated as galanin receptor 2. The invention also encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to additional methods and compositions which rely upon either GAL-R2 proteins or nucleic acids.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: August 5, 2008
    Assignee: National Research Council of Canada
    Inventors: Shi-Hsiang Shen, Sultan Ahmad, Claes Wahlestedt, Philippe Walker
  • Galanin receptor 2 proteins and nucleic acids
    Patent number: 7375207
    Abstract: The present invention is directed to galanin receptor 2 (GAL-R2) proteins and nucleic acids.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: May 20, 2008
    Assignee: AstraZeneca A.B.
    Inventors: Shi-Hsiang Shen, Sultan Ahmad, Claes Wahlestedt, Philippe Walker
  • G-protein coupled receptor
    Patent number: 7238780
    Abstract: The present invention is directed to a novel neurotensin-like receptor expressed in the central nervous system of humans. The invention encompasses the receptor protein as well as nucleic acids encoding the protein. In addition, the invention is directed to methods and compositions which utilize the receptor.
    Type: Grant
    Filed: July 14, 2004
    Date of Patent: July 3, 2007
    Assignee: Astrazeneca Canada Inc.
    Inventors: Sultan Ahmad, Jack Cao, Dajan O'Donnell, Philippe Walker
  • Novel galanin receptor
    Publication number: 20060234281
    Abstract: The present invention is directed to a novel receptor for galanin which has been designated as galanin receptor 2. The invention encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to methods and compositions which rely upon either GAL-R2 proteins or nucleic acids.
    Type: Application
    Filed: April 18, 2006
    Publication date: October 19, 2006
    Applicant: National Research Council of Canada
    Inventors: Shi-Hsiang Shen, Sultan Ahmad, Claes Wahlestedt, Philippe Walker
  • Novel galanin receptor
    Publication number: 20060234282
    Abstract: The present invention is directed to a novel receptor for galanin which has been designated as galanin receptor 2. The invention encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to methods and compositions which rely upon either GAL-R2 proteins or nucleic acids.
    Type: Application
    Filed: April 18, 2006
    Publication date: October 19, 2006
    Applicant: National Research Council of Canada
    Inventors: Shi-Hsiang Shen, Sultan Ahmad, Claes Wahlestedt, Philippe Walker
  • Novel galanin receptor
    Publication number: 20060235202
    Abstract: The present invention is directed to a novel receptor for galanin which has been designated as galanin receptor 2. The invention encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to methods and compositions which rely upon either GAL-R2 proteins or nucleic acids.
    Type: Application
    Filed: April 18, 2006
    Publication date: October 19, 2006
    Applicant: National Research Council of Canada
    Inventors: Shi-Hsiang Shen, Sultan Ahmad, Claes Wahlestedt, Philippe Walker
  • Receptor
    Publication number: 20050191295
    Abstract: The present invention is directed to a novel G protein-coupled receptor expressed, inter alia, in the central nervous system of rats. The invention encompasses the receptor protein as well as nucleic acids encoding the protein. In addition, the invention is directed to methods and compositions which utilize the receptor.
    Type: Application
    Filed: April 7, 2005
    Publication date: September 1, 2005
    Inventors: Sultan Ahmad, Cyrla Hoffert, Dajan O'Donnell, Manon Pelletier, Philippe Walker
  • Novel G-protein coupled receptor
    Publication number: 20050054045
    Abstract: The present invention is directed to a novel neurotensin-like receptor expressed in the central nervous system of humans. The invention encompasses the receptor protein as well as nucleic acids encoding the protein. In addition, the invention is directed to methods and compositions which utilize the receptor.
    Type: Application
    Filed: July 14, 2004
    Publication date: March 10, 2005
    Inventors: Sultan Ahmad, Jack Cao, Dajan O'Donnell, Philippe Walker
  • G-protein coupled receptor
    Patent number: 6800749
    Abstract: The present invention is directed to a novel neurotensin-like receptor expressed in the central nervous system of humans. The invention encompasses the receptor protein as well as nucleic acids encoding the protein. In addition, the invention is directed to methods and compositions which utilize the receptor.
    Type: Grant
    Filed: July 1, 1999
    Date of Patent: October 5, 2004
    Assignee: AstraZeneca Canada Inc.
    Inventors: Sultan Ahmad, Jack Cao, Dajan O'Donnell, Philippe Walker
  • Novel galanin receptor
    Publication number: 20030187222
    Abstract: The present invention is directed to a novel receptor for galanin which has been designated as galanin receptor 2. The invention encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to methods and compositions which rely upon either GAL-R2 proteins or nucleic acids.
    Type: Application
    Filed: February 6, 2003
    Publication date: October 2, 2003
    Applicant: AstraZeneca Canada Inc.
    Inventors: Shen Shi-Hsiang, Ahmad Sultan, Claes Wahlestedt, Philippe Walker
  • Galanin receptor
    Patent number: 6562945
    Abstract: The present invention is directed to a novel receptor for galanin which has been designated as galanin receptor 2. The invention encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to methods and compositions which rely upon either GAL-R2 proteins or nucleic acids.
    Type: Grant
    Filed: January 7, 1998
    Date of Patent: May 13, 2003
    Assignee: AstraZeneca Canada Inc.
    Inventors: Shen Shi-Hsiang, Ahmad Sultan, Claes Wahlestedt, Philippe Walker
  • Thyrotropin-releasing hormone receptor 2(TRHR-2)
    Patent number: 6441133
    Abstract: The present invention is directed to the novel receptor for TRH which has been designated as TRH receptor 2. The invention encompasses both the receptor protein as well as nucleic acids encoding the protein. In addition, the present invention is directed to methods and compositions which rely upon either TRHR-2 proteins or nucleic acids.
    Type: Grant
    Filed: January 27, 1998
    Date of Patent: August 27, 2002
    Assignee: AstraZeneca Canada Inc.
    Inventor: Philippe Walker